

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number  
**WO 01/62721 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 323/31**,  
317/32, 255/50, 217/54, 211/49, C07D 295/04, A61K  
31/00, A61P 29/00, 43/00

Charnwood, Bakewell Road, Loughborough LE11 5RH  
(GB).

(21) International Application Number: PCT/SE01/00371

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Prop-  
erty, S-151 85 Södertälje (SE).

(22) International Filing Date: 20 February 2001 (20.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0004151.7 23 February 2000 (23.02.2000) GB

(71) Applicant (for all designated States except US): **AS-  
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **CHESHIRE,**  
**David** [GB/GB]; AstraZeneca R & D Charnwood,  
Bakewell Road, Loughborough, Leics. LE11 5RH (GB).  
**CONNOLLY, Stephen** [GB/GB]; AstraZeneca R &  
D Charnwood, Bakewell Road, Loughborough LE11  
5RH (GB). **COX, David** [GB/GB]; AstraZeneca R & D  
Charnwood, Bakewell Road, Loughborough LE11 5RH  
(GB). **MILLICHIP, Ian** [GB/GB]; AstraZeneca R & D

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES



(57) Abstract: There is disclosed the use of a compound of formula (I), wherein R<sup>1</sup>, R<sup>2</sup>, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel

compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

WO 01/62721 A1

## NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES

Field of the Invention


5 The present invention relates to the use of phenylheteroalkylamine derivatives as inhibitors of the enzyme nitric oxide synthase. Certain novel phenylheteroalkylamine derivatives are also disclosed together with processes for their preparation, compositions containing them and their use in therapy.

10 Background of the Invention

Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one  
15 inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (ecNOS) is involved with smooth muscle relaxation and the regulation of blood pressure and blood flow, whereas the neuronal enzyme (ncNOS) serves as a neurotransmitter and appears to be involved in the regulation of various biological functions such as cerebral ischaemia. Inducible NOS has been particularly implicated in the pathogenesis of  
20 inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, *Ann. Rep. Med. Chem.*, 1996, **31**, 221 - 230).

Considerable effort has been expended in efforts to identify compounds that act as specific  
25 inhibitors of one or more isoforms of the enzyme nitric oxide synthase. The use of such compounds in therapy has also been widely claimed.

U.S. Patent 4,902,710 discloses novel compounds of formula




wherein  $R^1$  represents phenyl, substituted phenyl, C5 to 7 cycloalkyl, thienyl, halothienyl, (C1 to 4 alkyl)-substituted-thienyl, furanyl, pyridyl or thiazolyl;  $R^2$  and  $R^3$  are each independently H or methyl; n is 0, 1 or 2; and R can be, amongst other groups, substituted phenyl. Said compounds are potent and selective inhibitors of serotonin and norepinephrine uptake and are thereby claimed to be useful in the treatment of human diseases such as anxiety, depression and obesity.

The present invention relates to the surprising finding that a group of phenylheteroalkylamine derivatives, including some compounds that are within the generic scope of U.S. 4, 902,710, are inhibitors of the enzyme nitric oxide synthase.

#### Disclosure of the invention

According to the present invention, there is provided the use of a compound of formula (I)



wherein:

X and Y independently represent C1 to 4 alkyl, C1 to 4 alkoxy, halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C\equiv CH$ ,  $S(O)_mCH_3$ ,  $S(O)_pCF_3$ ,  $NO_2$  or  $NHCHO$ ;

m and p independently represent an integer 0, 1 or 2;

Z represents H or fluoro;

V represents  $S(O)_n$  or  $NR^3$ ;

W represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO<sub>2</sub> or NR<sup>4</sup>R<sup>5</sup>; said alkyl or alkoxy group  
5 being optionally further substituted by one or more fluorine atoms;

R<sup>1</sup> and R<sup>2</sup> independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR<sup>6</sup>R<sup>7</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms  
10 independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

or the group NR<sup>1</sup>R<sup>2</sup> together represents a 4 to 8 membered saturated azacyclic ring  
15 optionally incorporating one further heteroatom selected from O, S or NR<sup>8</sup>; said ring being optionally substituted by C1 to 4 alkyl, C1 to 4 alkoxy or OH; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH or NR<sup>9</sup>R<sup>10</sup>;

R<sup>3</sup> represents H or C1 to 4 alkyl;

20 R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> independently represent H or C1 to 4 alkyl;

R<sup>8</sup> represents H or C1 to 6 alkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH, NR<sup>11</sup>R<sup>12</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic  
25 ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

$R^{11}$  and  $R^{12}$  independently represent H or C1 to 4 alkyl;

n represents an integer 0, 1 or 2;

5 or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

10 In another aspect the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the inducible isoform of the enzyme nitric oxide synthase activity is beneficial.

15 A more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.

20 According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

25 Further, according to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of the activity of the inducible isoform of the enzyme nitric oxide synthase is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

30 More particularly, there is also provided a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease, wherein the

method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

5 In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

10

In another preferred aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or  
15 prophylaxis of diseases or conditions in which inhibition of the inducible isoform of the enzyme nitric oxide synthase activity is beneficial.

In another more particular aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a  
20 pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of inflammatory disease.

The compounds of the present invention may also be used advantageously in combination  
25 with a second pharmaceutically active substance, particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2). Thus, in a further aspect of the invention there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in combination with a COX-2 inhibitor for the treatment of inflammation, inflammatory disease and  
30 inflammatory related disorders. And there is also provided a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related

disorders in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof in combination with a COX-2 inhibitor.

5

In one preferred embodiment, V represents S. In another preferred embodiment, V represents NH.

10

In another preferred embodiment, X and Y independently represent Br, Cl, CH<sub>3</sub>, CF<sub>3</sub> or CN. It is particularly preferred that X represents Br, Cl or CF<sub>3</sub>. It is also particularly preferred that Y represents Cl or CN.

15

Preferably, W represents an optionally substituted five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N.

Preferably, R<sup>1</sup> and R<sup>2</sup> independently represent H or C1 to 4 alkyl optionally substituted by C1 to 4 alkoxy or hydroxy. More preferably, R<sup>1</sup> and R<sup>2</sup> independently represent H or methyl.

20

The use of the following compounds of formula (I) and pharmaceutically acceptable salts, enantiomers or racemates thereof is specifically included within the invention:

3-[(2,5-dichlorophenyl)thio]-N-methyl-benzenepropanamine;

2-[[3-(dimethylamino)-1-phenylpropyl]amino]-4-(trifluoromethyl)-benzonitrile;

4-chloro-2-[3-(methylamino)-1-phenylpropyl]amino]-benzonitrile;

25

4-chloro-2-{[3-(methylamino)-1-phenylpropyl]thio}benzonitrile;

4-bromo-2-{[3-(methylamino)-1-phenylpropyl]thio}benzonitrile;

3-[(2,5-dichlorophenyl)sulphonyl]-N-methylbenzenepropanamine;

(1*R*)-N<sup>1</sup>-[2-chloro-5-(trifluoromethyl)phenyl]-N<sup>3</sup>-methyl-1-phenyl-1,3-propanediamine;

2-[[1*R*]-3-amino-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile;

30

4-chloro-5-fluoro-2-[[1*R*]-3-(methylamino)-1-phenylpropyl]amino]benzonitrile;

*N*-(5-chloro-2-nitrophenyl)-1-phenyl-3-(morpholin-1-yl)propanamine;

- 2-[[*(1R)*-3-amino-1-phenylpropyl]thio]-4-chlorobenzonitrile;  
2-[[*(1R)*-3-amino-1-phenylpropyl]thio]-4-(trifluoromethyl)benzonitrile;  
 $\gamma$ -[(2,5-dimethylphenyl)thio]-*N*-methyl-benzenepropanamine;  
4-chloro-2-[methyl[3-(methylamino)-1-phenylpropyl]amino]benzonitrile;  
5 ( $\gamma^2R$ )- $\gamma$ -[(2,5-dichlorophenyl)thio]-2-thiazolepropanamine;  
 $\gamma$ -[(2,5-dichlorophenyl)thio]-2-oxazolepropanamine.

Unless otherwise indicated, the term "C1 to 4 alkyl" referred to herein denotes a straight or  
branched chain alkyl group having from 1 to 4 carbon atoms. Examples of such groups  
10 include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

The term "C1 to 6 alkyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C3 to 6 cycloalkyl" referred to herein denotes a  
15 cycloalkyl group having from 3 to 6 carbon atoms. Examples of such groups include  
cyclopropyl, cyclopentyl and cyclohexyl.

Unless otherwise indicated, the term "C1 to 4 alkoxy" referred to herein denotes a straight  
or branched chain alkoxy group having from 1 to 4 carbon atoms. Examples of such groups  
20 include methoxy, ethoxy, n-propoxy, i-propoxy and t-butoxy.

Examples of a "C1 to 4 alkyl or C1 to 4 alkoxy optionally further substituted by one or more  
fluorine atoms " include CF<sub>3</sub>, CF<sub>3</sub>CF<sub>2</sub>, CF<sub>3</sub>CH<sub>2</sub>, CH<sub>2</sub>FCH<sub>2</sub>, CH<sub>3</sub>CF<sub>2</sub>, CF<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>, OCF<sub>3</sub>  
and OCH<sub>2</sub>CF<sub>3</sub>.

25 Unless otherwise indicated, the term "halogen" referred to herein denotes fluoro, chloro,  
bromo and iodo.


Examples of a 4 to 8 membered saturated azacyclic ring optionally incorporating one  
30 further heteroatom selected from O, S or N include pyrrolidine, piperidine, piperazine,  
morpholine and perhydroazepine.



Examples of a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N include furan, thiophene, pyridine, thiazole, imidazole, oxazole, triazole, oxadiazole, thiadiazole and pyrimidine.

- 5 Examples of a five or six membered saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N include pyrrolidine, tetrahydrofuran, piperidine and piperazine.

Certain compounds of formula (I) are novel. Therefore a further aspect of the invention  
10 provides a compound of formula (Ia)



wherein

- 15 X and Y independently represent C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C≡CH, S(O)<sub>m</sub>CH<sub>3</sub>, S(O)<sub>p</sub>CF<sub>3</sub>, NO<sub>2</sub> or NHCHO;

m and p independently represent an integer 0, 1 or 2;

- 20 Z represents H or fluoro;

V represents S(O)<sub>n</sub> or NR<sup>3</sup>;

- W represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3  
25 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from

halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO<sub>2</sub> or NR<sup>4</sup>R<sup>5</sup>; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R<sup>1</sup> and R<sup>2</sup> independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group  
5 being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR<sup>6</sup>R<sup>7</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

10 or the group NR<sup>1</sup>R<sup>2</sup> together represents a 4 to 8 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S or NR<sup>8</sup>; said ring being optionally substituted by C1 to 4 alkyl, C1 to 4 alkoxy or OH; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH or NR<sup>9</sup>R<sup>10</sup>;

15 R<sup>3</sup> represents H or C1 to 4 alkyl;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> independently represent H or C1 to 4 alkyl;

20 R<sup>8</sup> represents H or C1 to 6 alkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH, NR<sup>11</sup>R<sup>12</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

25 R<sup>11</sup> and R<sup>12</sup> independently represent H or C1 to 4 alkyl;

n represents an integer 0, 1 or 2;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof,

with the proviso that when V represents  $S(O)_n$ ; and  $R^1$  and  $R^2$  independently represent H  
or methyl; and W represents phenyl, optionally substituted by halogen, C1 to 4 alkyl, C1 to  
3 alkoxy or  $CF_3$ ; or W represents thienyl, halothienyl, (C1 to 4 alkyl)-substituted-thienyl,  
furanlyl, pyridyl or thiazolyl; then at least one of X and Y represents  $OCF_3$ , CN,  $C\equiv CH$ ,  
 $S(O)_mCH_3$ ,  $S(O)_pCF_3$ ,  $NO_2$  or  $NHCHO$ .

According to the invention there is also provided a compound of formula (Ia), or a  
pharmaceutically acceptable salt, enantiomer or racemate thereof, for use as a medicament.

In one preferred embodiment, V in formula (Ia) represents S. In another preferred  
embodiment, V in formula (Ia) represents NH.

In another preferred embodiment, X and Y in formula (Ia) independently represent Br, Cl,  
 $CH_3$ ,  $CF_3$  or CN. It is particularly preferred that X represents Br, Cl or  $CF_3$ . It is also  
particularly preferred that Y represents Cl or CN.

Preferably, W in formula (Ia) represents an optionally substituted five or six membered  
aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S  
and N.

Preferably,  $R^1$  and  $R^2$  in formula (Ia) independently represent H or C1 to 4 alkyl optionally  
substituted by C1 to 4 alkoxy or hydroxy. More preferably,  $R^1$  and  $R^2$  independently  
represent H or methyl.

Particular compounds of formula (Ia) include:

2-[[3-(dimethylamino)-1-phenylpropyl]amino]-4-(trifluoromethyl)-benzonitrile;


4-chloro-2-[3-(methylamino)-1-phenylpropyl]amino]-benzonitrile;

4-chloro-2-{[3-(methylamino)-1-phenylpropyl]thio}benzonitrile;


- 4-bromo-2-{{[3-(methylamino)-1-phenylpropyl]thio} benzonitrile;  
 (1*R*)-*N*<sup>1</sup>-[2-chloro-5-(trifluoromethyl)phenyl]-*N*<sup>3</sup>-methyl-1-phenyl-1,3-propanediamine;  
 2-[[[(1*R*)-3-amino-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile;  
 4-chloro-5-fluoro-2-[[[(1*R*)-3-(methylamino)-1-phenylpropyl]amino]benzonitrile;  
 5 *N*-(5-chloro-2-nitrophenyl)-1-phenyl-3-(morpholin-1-yl)propanamine;  
 2-[[[(1*R*)-3-amino-1-phenylpropyl]thio]-4-chlorobenzonitrile;  
 2-[[[(1*R*)-3-amino-1-phenylpropyl]thio]-4-(trifluoromethyl)benzonitrile;  
 4-chloro-2-[methyl[3-(methylamino)-1-phenylpropyl]amino]benzonitrile;  
 γ-[(2,5-dichlorophenyl)thio]-2-oxazolepropanamine;  
 10 and pharmaceutically acceptable salts, enantiomers or racemates thereof.

According to the invention, we further provide a process for the preparation of compounds of formula (Ia), or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:

- 15 (a) reaction of a compound of formula (II)




wherein X, Y, V and Z are as defined in formula (Ia),  
 with a compound of formula (III)




wherein W, R<sup>1</sup> and R<sup>2</sup> are as defined in formula (Ia); or

- (b) reaction of a compound of formula (IV)




wherein X, Y and Z are as defined in formula (Ia) and  $L^1$  represents a leaving group,  
with a compound of formula (V)



wherein  $R^1$ ,  $R^2$ , V and W are as defined in formula (Ia); or

(c) reaction of a compound of formula (VI)




wherein X, Y, V, W and Z are as defined in formula (Ia) and  $L^2$  is a leaving group,  
with a compound of formula (VII)




wherein  $R^1$  and  $R^2$  are as defined in formula (Ia); or

(d) reaction of a compound of formula (II)




wherein X, Y, V and Z are as defined in formula (Ia),

with a compound of formula (VIII)



wherein  $R^1$ ,  $R^2$  and W are as defined in formula (Ia) and  $L^3$  is a leaving group; or

(e) reduction of a compound of formula (IX)



wherein X, Y, V, W and Z are as defined in formula (Ia) and G represents a group that upon reduction is converted into a group  $NR^1R^2$ ;

and where necessary converting the resultant compound of formula (Ia), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (Ia) into a further compound of formula (Ia); and where desired converting the resultant compound of formula (Ia) into an optical isomer thereof.

In process (a), the reactants (II) and (III) are coupled together in a suitable inert solvent such as tetrahydrofuran using, for example, Mitsunobu conditions. Thus, for example, the reactants are treated with a phosphine derivative and an azo derivative at a suitable

temperature, generally between 0 °C and the boiling point of the solvent. Suitable phosphine derivatives include triphenylphosphine and tributylphosphine. Suitable azo derivatives include diethyl azodicarboxylate, diisopropyl azodicarboxylate and 1,1'-(azodicarbonyl)dipiperidine.

5

In process (b), the reaction is performed by treating a nucleophile of formula (V) with an electrophile of formula (IV) in an inert solvent. Suitable leaving groups  $L^1$  include halides, particularly fluoride. The reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride. Suitable organic solvents are those such as

10 N-methyl-2-pyrrolidinone, tetrahydrofuran, C1 to 4 alcohols and dimethylsulfoxide. The reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

15

Alternatively, in process (b), the reaction will take place using an appropriate palladium source such as palladium (II) acetate in the presence of a suitable phosphine ligand such as BINAP.

20

In process (c), the amination reaction is performed by reacting a compound of formula (VI) with an amine (VII) in an inert solvent. Suitable leaving groups  $L^2$  include sulfonate, trifluorosulfonate, tosylate and halides selected from the group chloride, bromide or iodide. The nucleophile can be a primary or secondary amine in the presence of a base. This base can be either an excess of the amine nucleophile or can be an additive to the reaction mixture. Potential basic additives are metal carbonate, especially alkali metal carbonates, metal oxides and hydroxides, and tertiary amine bases. Suitable organic solvents are those

25 such as acetonitrile, dioxane, N,N-dimethylformamide, N-methyl-2-pyrrolidinone, tetrahydrofuran, dimethylsulfoxide, sulfolane and C1 to 4 alcohols.

30

In process (d), the reaction is performed by treating a nucleophile of formula (II) with an electrophile of formula (VIII) in an inert solvent. Suitable leaving groups  $L^3$  include halides, particularly chloride or bromide. The reaction is generally performed in the

presence of a non-nucleophilic base such as sodium hydride. Suitable organic solvents are those such as N-methyl-2-pyrrolidinone, tetrahydrofuran, C1 to 4 alcohols and dimethylsulfoxide. The reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

5

In process (e), G preferably represents an azido (N<sub>3</sub>) group. The required reduction may then be achieved by treating a compound of formula (IX) with a suitable reducing agent such as Sn(II) or triphenylphosphine. Preferably the reducing agent is triphenylphosphine and the reduction is carried out in a suitable inert solvent such as tetrahydrofuran.

10

It will be apparent to a person skilled in the art that in the above processes it may be desirable or necessary to protect an amine, hydroxyl or other potentially reactive group. Suitable protecting groups and details of processes for adding and removing such groups may be found by reference to the standard text "Protecting Groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts. In one preferred embodiment, amine groups are protected as carbamate derivatives, for example, as t-butyloxycarbamates. Thus, compounds of formula (Ia) in which R<sup>1</sup> is H are conveniently prepared by removal of a carbamate protecting group from a corresponding compound of formula (Ia) wherein R<sup>1</sup> is a carbamate group, especially a t-butyloxycarbamate group. Removal of the carbamate group is conveniently effected using hydrogen chloride in dioxan.

15

20

The present invention includes compounds of formula (Ia) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.

25

30

Salts of compounds of formula (Ia) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid. The



reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.

Certain novel intermediates of formulae (III), (V), (VI), (VIII) and (IX) form another aspect of the invention.

Compounds of formula (III) may be prepared by reaction of a compound of formula (X)



wherein  $\text{R}^1$  and  $\text{R}^2$  are as defined in formula (Ia),

with an organometallic derivative,  $\text{W}-\text{M}$ , wherein W is as defined in formula (Ia) and M represents a metallic residue such as lithium or magnesium-halide.

Compounds of formula (IX) may be prepared by:

(a) reacting a compound of formula (II), as defined above, with a compound of formula (XI)



wherein W and G are as defined above; or

(b) reacting a compound of formula (IV), as defined above, with a compound of formula (XII)



wherein V, W and G are as defined above.

Compounds of formulae (II), (IV), (VII), (X), (XI) and (XII) are either known or may be prepared using known methods. Some such methods are illustrated within the Examples that are included herein. Other suitable methods will be readily apparent to the man skilled  
5 in the art.

Intermediate compounds may be used as such or in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts.

10 The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

The compounds of formula (Ia) may exist in enantiomeric forms. Therefore, all enantiomers,  
15 diastereomers, racemates and mixtures thereof are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC.

Intermediate compounds may also exist in enantiomeric forms and may be used as purified  
20 enantiomers, diastereomers, racemates or mixtures.

The compounds of formula (Ia), and their pharmaceutically acceptable salts, enantiomers and racemates, are useful because they possess pharmacological activity in animals. In particular, the compounds of formulae (I) and (Ia) are active as inhibitors of the enzyme nitric oxide  
25 synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase.

30 The compounds of formulae (I) and (Ia) and their pharmaceutically acceptable salts, enantiomers and racemates are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory

part. In particular, the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.

Conditions that may be specifically mentioned are:

- 5 osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints;  
eczema, psoriasis, dermatitis or other inflammatory skin conditions such as sunburn;  
inflammatory eye conditions including uveitis, glaucoma and conjunctivitis;  
lung disorders in which inflammation is involved, for example, asthma, bronchitis, chronic  
10 obstructive pulmonary disease, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome;  
bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain, meningitis and pancreatitis;  
conditions of the gastrointestinal tract including inflammatory bowel disease, Crohn's  
15 disease, atrophic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome, reflux oesophagitis, damage to the gastrointestinal tract resulting from infections by, for example, *Helicobacter pylori*, or from treatments with non-steroidal anti-inflammatory drugs;  
and other conditions associated with inflammation.

20

By virtue of their pharmacological activity as inhibitors of the enzyme nitric oxide synthase, the compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.

- 25 We are particularly interested in the conditions inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease and pain.

- The compounds of formulae (I) and (Ia) and their pharmaceutically acceptable salts, enantiomers and racemates may also be useful in the treatment or prophylaxis of diseases or  
30 conditions in addition to those mentioned above. For example, the compounds may be useful in the treatment of atherosclerosis, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in

the maintenance of pancreatic function in diabetes, in the treatment of vascular complications associated with diabetes and in co-therapy with cytokines, for example TNF or interleukins.

The compounds of formulae (I) and (Ia) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and AIDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's Syndrome, Huntington's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Korsakoff's disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, autism, seasonal affective disorder, jet-lag and septic shock. Compounds of formulae (I) and (Ia) may also be expected to show activity in the prevention and reversal of drug addiction or tolerance such as tolerance to opiates and diazepines, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.

We are particularly interested in the conditions stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, migraine, cancer and septic shock.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.

The compounds of formula (Ia), and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral,  
5 sublingual or rectal), intranasal, intravenous, topical or other parenteral routes.

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a  
10 compound of formula (Ia), or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

15 The compounds of formulae (I) and (Ia), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX-2 inhibitor. Particularly preferred COX-2 inhibitors are Celecoxib and MK-966. The NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for  
20 administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.

The invention is illustrated, but in no way limited, by the following examples:

#### 25 Example 1

##### 3-[(2,5-Dichlorophenyl)thio]-N-methyl-benzenepropanamine fumarate

2,5-Dichlorobenzenethiol (394 mg, 2.2 mmol) and 3-chloro-N-methyl-benzenepropanamine hydrochloride (440 mg, 2.0 mmol) were added sequentially to an ethanolic solution of  
30 sodium ethoxide [prepared from sodium (140 mg, 6.0 mmol)] in dry ethanol (32 ml) and the mixture heated under reflux with stirring for 1.5h. The reaction mixture was cooled, evaporated, and the residue partitioned between water and ethyl acetate. The organic layer

was separated, washed with brine and dried over magnesium sulphate. The solvent was evaporated and the residue eluted down a flash chromatography column using 10% methanol/ dichloromethane as eluent to give 320 mg of the product as the free base. This oil was dissolved in dry ethanol (10 ml) and treated with fumaric acid (114 mg). The mixture  
5 was heated under reflux with stirring for 0.5 h. The solvent was evaporated and the residual solid was triturated with acetonitrile to give 410 mg (46%) of the title compound as a cream solid.

MS APCI +ve  $m/z$  326 ( $[M+H]^+$ ).

10  $^1H$  NMR 300MHz ( $d_6$ -DMSO) 7.45 (4H, m), 7.35 (2H, t), 7.25 (2H, m), 6.45 (2H, s), 4.82 (1H, t), 2.78 (1H, m), 2.65 (1H, m), 2.42 (3H, s), 2.22 (2H, m).

### Example 2

15 2-[[3-(Dimethylamino)-1-phenylpropyl]amino]-4-(trifluoromethyl)-benzonitrile  
2-Fluoro-4-(trifluoromethyl)benzonitrile (0.15 ml, 1.1 mmol) and  $N^3, N^3$ -dimethyl-1-phenyl-1,3-propanediamine (420 mg, 2.4 mmol) in n-butanol (0.5 ml) were stirred and heated under reflux for 20 h. The crude reaction mixture was applied to a silica column and the product eluted with 50% isohexane-diethyl ether. The title compound was isolated as a  
20 pale yellow coloured solid (330 mg, 86%).

MS APCI +ve  $m/z$  348 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz ( $CDCl_3$ ) 8.94 (1H, d), 7.4-7.16 (6H, m), 6.67 (1H, dd), 6.39 (1H, s),  
25 4.59 (1H, q), 2.46-2.38 (1H, m), 2.31-2.24 (7H, m), 2.14-2.07 (1H, m), 1.8-1.73 (1H, m).

### Example 3

4-Chloro-2-[3-(methylamino)-1-phenylpropyl]amino]-benzonitrile

a) 4-Chloro-2-[(3-hydroxy-1-phenylpropyl)amino]-benzonitrile

A mixture of 3-amino-3-phenyl-1-propanol (1 g, 6.6 mmol), 4-chloro-2-fluorobenzonitrile (1 g, 6.4 mmol) and N,N-diisopropylethylamine (1.2 ml, 6.9 mmol) was stirred and heated at 140 °C for 5 h. The crude reaction mixture was cooled and purified on silica gel  
5 (ether/isohexane 1:4). The product was isolated as a colourless solid (1.1 g, 58%), m.p. 88 - 90 °C.

MS APCI +ve  $m/z$  287 ( $[M+H]^+$ ).

10  $^1H$  NMR 300MHz ( $d_6$ -DMSO) 7.5-7.2 (6H, m), 7.05 (1H, d), 6.63 (1H, dd), 6.51 (1H, d), 4.9 (1H, t), 4.73 (1H, q), 3.49 (2H, q), 2.1-1.88 (2H, m).

b) 4-Chloro-2-[(3-iodo-1-phenylpropyl)amino]-benzonitrile

To a solution of triphenylphosphine (1.83 g, 6.98 mmol) in dry tetrahydrofuran (30 ml) at  
15 0 °C and under an atmosphere of nitrogen was added diethyl azodicarboxylate (1.2 g, 6.9 mmol) dropwise. After 20 minutes, lithium iodide and 4-chloro-2-[(3-hydroxy-1-phenylpropyl)amino]-benzonitrile (0.8 g, 2.79 mmol) were added to the mixture and stirring was continued for 5 h. The mixture was then concentrated to dryness, and the residue purified on silica (ether/isohexane 1:4). The title compound was isolated as a colourless  
20 solid (0.35 g, 32%).

$^1H$  NMR 400MHz ( $CDCl_3$ ) 7.41-7.28 (6H, m), 6.65 (1H, d), 6.5 (1H, d), 4.94 (1H, br d), 4.6 (1H, q), 3.28-3.23 (1H, m), 3.1-3.04 (1H, m), 2.43-2.26 (2H, m).

c) 4-Chloro-2-[3-(methylamino)-1-phenylpropyl]amino]-benzonitrile

To a solution of methylamine (3 ml) in methanol (20 ml), was added 4-chloro-2-[(3-iodo-1-phenylpropyl)amino]-benzonitrile (0.35 g, 0.88 mmol). The mixture was stirred at ambient temperature for 20 h, then concentrated to dryness. The residue was purified by chromatography on silica gel (7N methanolic ammonia/dichloromethane, 1:9) to afford the  
30 title compound as a pale pink coloured solid (169 mg, 64%), m.p. 119 - 120 °C.

MS APCI +ve  $m/z$  300/302 ( $[M+H]^+$ ).

<sup>1</sup>H NMR 300MHz (CDCl<sub>3</sub>) 8.22 (1H, d), 7.37-7.24 (6H, m), 6.52 (1H, dd), 6.27 (1H, d), 4.58 (1H, q), 2.8-2.66 (2H, m), 2.48 (3H, s), 2.14-2.05 (1H, m), 1.89-1.8 (1H, m).

5

#### Example 4

##### 4-Chloro-2-{{3-(methylamino)-1-phenylpropyl}thio}benzonitrile hydrochloride

##### a) [3-(Acetylthio)-3-phenylpropyl]methylcarbamic acid, 1,1-dimethylethyl ester

10 To a stirred solution of triphenylphosphine (1.13 g, 4.32 mmol) in dry tetrahydrofuran (12 ml) was added diisopropyl azodicarboxylate (0.88 ml, 4.32 mmol) dropwise with stirring at 0 °C under nitrogen. After 0.5 h, a solution of (3-hydroxy-3-phenylpropyl)carbamic acid 1,1-dimethylethyl ester (0.572 g, 2.16 mmol) and thiolacetic acid (0.31 ml, 4.34 mmol) in dry tetrahydrofuran (10 ml) was added slowly at 0 °C. The  
15 mixture was stirred at this temperature for 1 h, then stirred at room temperature overnight. The mixture was evaporated, and then eluted down a flash chromatography column using ether/isohexane (1:9) as eluent to give the product (420 mg, 60%) as a cream coloured solid.

MS APCI +ve <sup>m/z</sup> 224 ([M+H]<sup>+</sup>).

20

##### b) 4-Chloro-2-{{3-(methylamino)-1-phenylpropyl}thio}benzonitrile hydrochloride

[3-(Acetylthio)-3-phenylpropyl]methylcarbamic acid 1,1-dimethylethyl ester (300 mg, 0.928 mmol) in ethanol (20 ml) was treated with sodium hydroxide in water (5 ml) followed by 4-chloro-2-fluorobenzonitrile (144 mg, 0.928 mmol) and the mixture stirred at room  
25 temperature under nitrogen overnight. The reaction mixture was heated under reflux for 0.5 h, cooled, poured into water and extracted with ethyl acetate which was washed with brine and dried over magnesium sulphate. The solvent was evaporated and the residue eluted down a flash chromatography column using ether/isohexane (3:7) as eluent to give 160 mg of the carbamate protected product as a colourless oil. This material was stirred  
30 with 4M hydrogen chloride in dioxan (6 ml) for 1.5 h, evaporated, triturated with ether to give the title compound (122 mg, 37%) as a colourless solid.



MS APCI +ve  $m/z$  317 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz ( $d_6$ -DMSO) 8.76 (2H, brs), 7.83 (1H, d), 7.71 (1H, d), 7.48 (1H, d of d), 7.43-7.26 (5H, m), 4.96 (1H, t), 2.94 (1H, br m), 2.75 (1H, br m), 2.50 (3H, s), 2.28 (2H, m).

#### Example 5

##### 4-Bromo-2- $\{[3-(methylamino)-1-phenylpropyl]thio\}$ benzonitrile oxalate

Prepared by the method of Example 5 using [3-(acetylthio)-3-phenylpropyl]methylcarbamic acid 1,1-dimethylethyl ester and 4-bromo-2-fluorobenzonitrile to give the title compound which was isolated as the oxalate salt.

MS APCI +ve  $m/z$  363 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz ( $d_6$ -DMSO) 7.77 (1H, d), 7.73 (1H, s), 7.62 (1H, d of d), 7.41-7.26 (6H, m), 4.87 (1H, t), 2.97 (1H, m), 2.75 (1H, m), 2.53 (3H, s), 2.27 (2H, m).

#### Example 6

##### 3- $[(2,5-Dichlorophenyl)sulphonyl]$ -N-methylbenzenepropanamine trifluoroacetate

The product from Example 1 (90 mg, 0.203 mmol) was stirred as a suspension in a 1:1 mixture of methanol/water (1 ml) under nitrogen at room temperature. Oxone® (375 mg, 0.61 mmol) was then added and the reaction mixture stirred for 4.5 h. The reaction was neutralised with sodium bicarbonate and extracted with dichloromethane which was dried over anhydrous sodium sulphate. The solvent was evaporated, the residue purified by reverse phase HPLC and the clean fractions freeze-dried to give the required product (8 mg, 8%) as the trifluoroacetate salt.

MS APCI +ve  $m/z$  358 ( $[M+H]^+$ ).

<sup>1</sup>H NMR 300MHz (d<sub>6</sub>-DMSO) 7.78 (2H, m), 7.54 (1H, m), 7.36-7.26 (5H, m), 4.98 (1H, d of d), 3.30 (3H, s), 2.97 (1H, m), 2.64 (1H, m), 2.52 (2H, m).

5

### Example 7

(1R)-N<sup>1</sup>-[2-Chloro-5-(trifluoromethyl)phenyl]-N<sup>3</sup>-methyl-1-phenyl-1,3-propanediamine oxalate

10

a) N-[2-Chloro-5-(trifluoromethyl)phenyl]-α-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl-(α<sup>1</sup>R)-benzenemethanamine

15

2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (32.3 mg, 0.052 mmol) and palladium (II) acetate (23.3 mg, 0.104 mmol) were stirred at room temperature in toluene (5 ml) for 10 minutes. 2-Bromo-1-chloro-4-(trifluoromethyl)benzene (270 mg, 1.25 mmol) was added and the resulting mixture stirred for a further 10 minutes. (α<sup>1</sup>R)-α-{2-[(1,1-Dimethylethyl)dimethylsilyl]oxy}ethyl}benzenemethanamine (330 mg, 1.25 mmol) was added, and after another 10 minutes sodium tert-butoxide (140 mg, 1.45 mmol) was added and the reaction mixture heated to 120 °C overnight. The reaction was cooled, diluted with ether, filtered through celite and the filtrate evaporated to give 400 mg of crude product which was used directly in the next step.

20

b) (γ<sup>1</sup>R)-γ-{[2-Chloro-5-(trifluoromethyl)phenyl]amino}benzenepropanol

25

The crude product from Example 7(a) (400 mg) was dissolved in tetrahydrofuran (10 ml) and tetrabutylammonium fluoride (1M solution in tetrahydrofuran; 1.87 ml) was added at room temperature. The mixture was stirred for 5 h, evaporated and the residue partitioned between ethyl acetate and water. The aqueous layer was separated and extracted with more ethyl acetate (2 x), and the extracts combined and dried over anhydrous sodium sulphate. The solvent was evaporated and the residue eluted down a flash chromatography column using 10% methanol/dichloromethane as eluent to give product (148 mg) as a colourless oil.

30

<sup>1</sup>H NMR 300MHz (d<sub>6</sub>-DMSO) 7.48 (1H, d), 7.35 (4H, m), 7.22 (1H, t), 6.83 (1H, d), 6.65 (1H, s), 6.51 (1H, d), 4.88 (1H, m), 4.70 (1H, m), 3.52 (2H, m), 2.00 (2H, m).

5 c) (1R)-N<sup>1</sup>-[2-Chloro-5-(trifluoromethyl)phenyl]-N<sup>3</sup>-methyl-1-phenyl-1,3- propanediamine oxalate

The product of Example 7(b) (148 mg, 0.449 mmol) and triphenylphosphine (141 mg, 0.539 mmol) were stirred together in dry tetrahydrofuran (10 ml) at 0 °C.

N-iodosuccinimide (121 mg, 0.539 mmol) was added and the reaction mixture allowed to  
10 warm to room temperature overnight. After treatment with more triphenylphosphine (282 mg, 1.08 mmol) and N-iodosuccinimide (242 mg, 1.08 mmol), and stirring for a further 24 h, the reaction mixture was treated with aqueous methylamine (40%, 1.0 ml) and stirred for 5 h at room temperature. The reaction mixture was evaporated, the residue purified by reverse phase HPLC and the isolated product converted into the oxalate salt to  
15 give a colourless solid (37.2 mg, 16%).

MS APCI +ve <sup>m/z</sup> 343 ([M+H]<sup>+</sup>).

<sup>1</sup>H NMR 300MHz (d<sub>6</sub>-DMSO) 7.47 (1H, d), 7.43 (2H, d), 7.35 (2H, t), 7.24(1H, t),  
20 6.87(1H, d), 6.78(1H, s), 6.28 (1H, d), 4.74 (1H, q), 2.96 (2H, m), 2.57 (3H, s), 2.36 (1H, m), 2.05(1H, m).

### Example 8

25 2-[[[(1R)-3-Amino-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile

a) 4-Chloro-5-fluoro-2-[[[(1R)-3-hydroxy-1-phenylpropyl]amino]benzonitrile

4-Chloro-2,5-difluorobenzonitrile (1.0 g, 5.76 mmol) and (γ<sup>1</sup>R)-γ-aminobenzenepropanol (870 mg, 5.76 mmol) were heated in N,N-diisopropylethylamine (740 mg, 5.76 mmol) at  
30 140 °C for 30 h. The reaction mixture was partitioned between ethyl acetate and water and

the organic layer separated. The aqueous layer was further extracted with ethyl acetate, and the extracts combined and dried over anhydrous sodium sulphate. The solvent was evaporated and the residue purified by flash chromatography using 10% ethyl acetate/isohehexane as eluent to give the title product (260 mg, 15%).

MS APCI + ve  $m/z$  305 ( $[M+H]^+$ ).

$^1\text{H}$  NMR 300MHz ( $\text{CDCl}_3$ ) 7.33 (5H, m), 7.15 (1H, d), 6.43 (1H, d), 5.98 (1H, d), 4.61 (1H, d), 3.79 (2H, m), 2.11 (2H, m).

b) 4-Chloro-5-fluoro-2-[[*(1R)*-3-iodo-1-phenylpropyl]amino]benzonitrile

The product of Example 8(a) (260 mg, 0.86 mmol) and triphenylphosphine (270 mg, 1.03 mmol) in dry tetrahydrofuran (15 ml) were cooled to 0 °C and treated with N-iodosuccinimide (230 mg, 1.03 mmol). The reaction mixture was stirred to room temperature overnight and divided for further manipulation.

c) 2-[[*(1R)*-3-Azido-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile

Half of the crude solution from Example 8(b) was treated with sodium azide (59 mg, 0.9 mmol) in dry dimethylsulphoxide (5 ml) and stirred for 2 h at room temperature. The reaction mixture was partitioned between ethyl acetate and water and the organic layer separated. The aqueous was further extracted with ethyl acetate (2 x) and the extracts combined, washed with brine and dried over anhydrous sodium sulphate. The solvent was evaporated and the crude product used for the next step.

d) 2-[[*(1R)*-3-Amino-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile hydrochloride

The crude azide from Example 8(c) (108 mg) was dissolved in anhydrous methanol (10 ml), anhydrous stannous chloride (186 mg) was added and the reaction stirred for 1 h. The reaction mixture was filtered through celite and the filtrate concentrated to dryness. The residue was passed down a SCX ion exchange column initially using methanol as

eluent and then aqueous ammonia to give an oil which was converted into the hydrochloride salt, giving a yellow solid (60 mg).

MS APCI +ve  $m/z$  304 ( $[M+H]^+$ ).

5

$^1H$  NMR 300MHz ( $d_6$ -DMSO) 7.92 (3H, br s), 7.73 (1H, d), 7.47 (1H, d), 7.37 (2H, t), 7.27 (1H, t), 6.80 (2H, m), 4.74 (1H, q), 2.81 (2H, m), 2.14 (2H, m).

#### Example 9

10

#### 4-Chloro-5-fluoro-2-[[[(1R)-3-(methylamino)-1-phenylpropyl]amino]benzonitrile hydrochloride

15

Half of the crude solution from Example 8(b) was treated with 40% aqueous methylamine (0.06 ml) and the reaction mixture stirred overnight at room temperature. The mixture was concentrated and the residue passed down a SCX ion exchange column initially eluting with methanol then aqueous ammonia to give an oil which was converted into the hydrochloride salt to give a colourless foam (26 mg).

MS APCI +ve  $m/z$  318 ( $[M+H]^+$ ).

20

$^1H$  NMR 300MHz ( $d_6$ -DMSO) 8.71 (1H, s), 7.73 (1H, d), 7.47(2H, d), 7.37 (2H, t), 7.27 (1H, t), 6.81 (2H, m), 4.76 (1H, m), 2.92 (2H, m), 2.55 (3H, s), 2.32 (1H, m), 2.05 (1H, m).

#### Example 10

25

#### N-(5-Chloro-2-nitrophenyl)-1-phenyl-3-(morpholin-1-yl)propanamine fumarate

30

A mixture of 4-chloro-2-fluoronitrobenzene (900 mg, 5.13 mmol) and 1-phenyl-3-(morpholin-1-yl)propanamine (1.13 g, 5.13 mmol) in acetonitrile (50 ml) was heated under reflux for 2 h. The cooled reaction mixture was then quenched with 2N aqueous hydrochloric acid (200 ml), and the products extracted into diethyl ether (2 x 100 ml). The

aqueous phase was collected, basified with solid potassium carbonate to pH 14, and extracted with ethyl acetate (2 x 150 ml). The combined extracts were dried over magnesium sulphate, filtered and concentrated to an oil. The crude product was purified on silica gel using ethyl acetate as eluent to give an oil (1 g, 52%). The amine was converted  
5 into the fumarate salt by addition of fumaric acid (1 equivalent) in ethanol (10 ml) and the product collected by filtration. After recrystallisation from ethanol, a yellow solid (380 mg, 18%) was obtained.

MS APCI +ve  $m/z$  376 ( $[M+H]^+$ ).

$^1H$  NMR 400MHz ( $d_6$ -DMSO) 8.89 (1H, d), 8.09 (1H, d), 7.43-7.25 (5H, m), 6.84 (1H, d), 6.68 (1H, dd), 6.62 (2H, s), 4.96 (1H, dd), 3.69-3.63 (4H, m), 2.5-2.3 (6H, m), 2.15-1.97 (2H, m).

### Example 11

#### 2-[[[(1R)-3-Amino-1-phenylpropyl]thio]-4-chlorobenzonitrile fumarate

##### a) $\alpha$ -(2-Azidoethyl)-( $\alpha^1S$ )- benzenemethanol

( $\alpha^1S$ )- $\alpha$ -(2-Chloroethyl)benzenemethanol (1.68 g, 9.85 mmol) and sodium azide (960 mg, 1.5 eq.) in wet DMSO (15 ml + water 0.5 ml) were stirred and heated at 50 °C for 17 h. The reaction mixture was diluted with water (300 ml) and the products extracted into diethyl ether (2 x 200 ml). The combined extracts were dried (magnesium sulphate) and concentrated to an oil. Purification was achieved on silica gel eluting with 10%  
25 acetone/isohexane to afford the azide as a colourless oil (1.6 g, 92%).

$^1H$  NMR 300MHz ( $CDCl_3$ ) 7.41-7.27 (5H, m), 4.88-4.82 (1H, m), 3.55-3.35 (2H, m), 2.11-1.89 (3H, m).

##### b) $\alpha$ -(2-Azidoethyl)- ( $\alpha^1R$ )- benzenemethanethiol

To a solution of tris(4-chlorophenyl)phosphine (7.82 g, 21.4 mmol) in dry tetrahydrofuran was added diethyl azodicarboxylate (4 ml, 1.2 eq.), and the mixture stirred at ambient temperature for 15 minutes. The product of Example 11(a) (3.8 g, 21.4 mmol) was added to the mixture followed by thiobenzoic acid (2.96 g, 1 eq.). The resulting orange solution was stirred overnight. The mixture was then treated with sodium methoxide in methanol (10 ml, 25 wt%, 46 mmol). After 10 minutes the mixture was poured into water (100 ml) and made acidic by addition of 4M hydrochloric acid. The products were extracted into ethyl acetate (200 ml), and the extract dried (magnesium sulphate) and concentrated to a dark green oil. Purification was achieved on silica gel eluting with 1% ethyl acetate in isohexane and afforded the thiol as an orange oil (1.4 g, 34%).

<sup>1</sup>H NMR 300MHz (CDCl<sub>3</sub>) 7.4-7.2 (5H, m), 4.12 (1H, q), 3.44-3.22 (2H, m), 2.24-2.1 (2H, m), 1.96 (1H, d).

c) 2-[[[(1R)-3-Azido-1-phenylpropyl]thio]-4-chlorobenzonitrile

To a stirred solution of the product of Example 11(b) (620 mg, 3.2 mmol) and 4-chloro-2-fluorobenzonitrile (500 mg, 3.2 mmol) in dry tetrahydrofuran (20 ml) was added sodium hydride (130 mg, 60% dispersion in mineral oil, 3.2 mmol). The mixture was stirred at ambient temperature for 2 h, then diluted with water (150 ml). The products were extracted into diethyl ether (100 ml), and the extract dried (magnesium sulphate) and concentrated. The crude product was purified on silica gel eluting with 20% diethyl ether/isohexane and afforded the title compound as a colourless solid (500 mg, 48%).

<sup>1</sup>H NMR 300MHz (CDCl<sub>3</sub>) 7.7-7.2 (8H, m), 4.52 (1H, dd), 3.53-3.24 (2H, m), 2.32-2.2 (2H, m).

d) 2-[[[(1R)-3-Amino-1-phenylpropyl]thio]-4-chlorobenzonitrile fumarate

The azide of Example 11(c) (500 mg, 1.53 mmol) in tetrahydrofuran (30 ml) was treated with triphenylphosphine (600 mg, 2.3 mmol) and water (0.3 ml). The mixture was then stirred and heated under reflux for 1.5 h. The cooled solution was concentrated to dryness,

and the residue purified on silica gel eluting with 10% 7N ammonia in methanol/dichloromethane. The amine was isolated as a colourless oil and was converted into a fumarate salt with 1 equivalent of fumaric acid in ethanol to give a colourless solid (490 mg, 51%).

MS APCI +ve  $m/z$  303 ( $[M+H]^+$ ).

$^1H$  NMR 400MHz ( $d_6$ -DMSO) 7.82-7.25 (8H, m), 6.42 (~1.3H, s), 4.95 (1H, t), 2.83-2.63 (2H, m), 2.25-2.18 (2H, m).

#### Example 12

##### 2-[[*(1R)*-3-Amino-1-phenylpropyl]thio]-4-(trifluoromethyl)benzonitrile fumarate

The title compound was prepared in the same manner as Example 11 but using 2-fluoro-4-(trifluoromethyl)benzonitrile and was isolated as a fumarate salt (600 mg, 63%).

MS APCI +ve  $m/z$  337 ( $[M+H]^+$ ).

$^1H$  NMR 400MHz ( $d_6$ -DMSO) 8.01 (1H, d), 7.83 (1H, s), 7.71 (1H, d), 7.4-7.22 (5H, m), 6.41 (~1.3H, s), 5.02 (1H, t), 2.85-2.67 (2H, m), 2.27-2.21 (2H, m).

#### Example 13

##### $\gamma$ -[(2,5-Dimethylphenyl)thio]-*N*-methyl-benzenepropanamine hydrochloride

Prepared by the procedure described in Example 1, but using 2,5-dimethylbenzenethiol and diisopropylethylamine (8.5 equivalents) in methanol in preference to sodium ethoxide. The amine was isolated as a hydrochloride salt by treatment with hydrogen chloride in diethyl ether.

MS APCI +ve  $m/z$  286 ( $[M+H]^+$ ).



<sup>1</sup>H NMR 300MHz (d<sub>6</sub>-DMSO) 8.87 (2H, br s), 7.35-6.94 (8H, m), 4.49 (1H, t), 2.96-2.86 (1H, m), 2.72-2.66 (1H, m), 2.48 (3H, s), 2.29-2.17 (8H, m).

5

#### Example 14

#### 4-Chloro-2-[methyl[3-(methylamino)-1-phenylpropyl]amino]benzonitrile oxalate

##### a) 4-Chloro-2-[(3-hydroxy-1-phenylpropyl)amino]benzonitrile

10 A mixture of 3-amino-3-phenylpropanol (1 g, 6.6 mmol) and 4-chloro-2-fluorobenzonitrile (1 g, 6.4 mmol) in diisopropylethylamine (1.2 ml, 6.9 mmol) was heated at 140 °C for 5 h. The crude reaction mixture was cooled to room temperature and applied to a silica column. The title compound was isolated as a colourless solid (1.1 g, 58%) by elution with 20% diethyl ether/isohexane.

15

MS APCI +ve <sup>m/z</sup> 287 ([M+H]<sup>+</sup>).

##### b) 4-Chloro-2-[[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-phenylpropyl]amino]benzonitrile

20 A solution of 4-chloro-2-[(3-hydroxy-1-phenylpropyl)amino]benzonitrile (2.3 g, 8 mmol) in dry tetrahydrofuran (50 ml) was treated with tert-butyldimethylsilylchloride (2.41 g, 2 eq.) and imidazole (1.09 g, 2 eq.) and stirred at room temperature for 1 h. The reaction mixture was diluted with water (200 ml) and the products extracted into diethyl ether (200 ml). The organic extract was dried over magnesium sulphate and concentrated to an oil. The crude product was purified on silica gel eluting with isohexane/diethyl ether (2:1) to afford the title compound as a colourless oil (2.3 g, 72%).

25

<sup>1</sup>H NMR 400MHz (CDCl<sub>3</sub>) 7.35-7.15 (6H, m), 6.52 (1H, d), 6.41 (1H, s), 5.42 (1H, d), 4.58 (1H, q), 3.7-3.5 (2H, m), 2.0 (2H, m), 0.83 (9H, s), 0.0 (6H, s).

30

c) 4-Chloro-2-[(3-hydroxy-1-phenylpropyl)methylamino]benzonitrile

To a stirred suspension of sodium hydride (60% dispersion, 270 mg, 6.75 mmol) in dry tetrahydrofuran (20 ml) under nitrogen and at 0 °C was added 4-chloro-2-[[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-phenylpropyl]amino]benzonitrile (2.3 g, 5.74 mmol) in tetrahydrofuran (10 ml). The resulting yellow suspension was stirred at room temperature for 2 h, and then treated with methyl iodide (3.6 ml, 57.4 mmol). The resulting mixture was heated under reflux for 10 h, and then treated with acetic acid (10 ml) and water (2 ml). Heating and stirring were continued overnight. The mixture was concentrated under vacuum and the residue partitioned between water (50 ml) and ethyl acetate (100 ml). The organic extract was collected and dried over magnesium sulphate. After concentration of the extract the residue was purified on silica gel using 80% isohexane/diethyl ether as eluent. The title compound was isolated as a colourless oil (1 g, 58%).

<sup>1</sup>H NMR 400MHz (CDCl<sub>3</sub>) 7. 51-6.76 (8H, m), 5.13 (1H, t), 3.8-3.72 (2H, m), 2.69 (3H, s), 2.39-2.33 (2H, m).

d) 4-Chloro-2-[(3-chloro-1-phenylpropyl)methylamino]benzonitrile

4-Chloro-2-[(3-hydroxy-1-phenylpropyl)methylamino]benzonitrile (1 g, 3.3 mmol) was dissolved in thionyl chloride (10 ml). To the solution was added diisopropylethylamine (0.1 ml, 0.57 mmol) and the mixture stirred at room temperature for 15 minutes, then concentrated to dryness under vacuum. The crude material was purified on silica gel (eluting with 20% diethyl ether/isohexane) to afford the chloride as a colourless oil (330 mg, 31%).

GC/MS <sup>m/z</sup> 318/20/22 ([M]<sup>+</sup>).

e) 4-Chloro-2-[methyl[3-(methylamino)-1-phenylpropyl]amino]benzonitrile oxalate

4-Chloro-2-[(3-chloro-1-phenylpropyl)methylamino]benzonitrile (300 mg, 0.94 mmol) was dissolved in a saturated solution of methylamine in methanol (7 ml) and the mixture heated in a pressure vessel at 140 °C for 24 h. The mixture was concentrated, and the residue

purified on a silica column eluting with 10% 7N ammonia in methanol /dichloromethane. The title compound was isolated as an oxalate salt (30 mg, 10%).

MS APCI +ve  $m/z$  314 ( $[M+H]^+$ ).

$^1H$  NMR 300MHz ( $d_6$ -DMSO) 7.75 (1H, d), 7.45-6.98 (7H, m), 5.01 (1H, t), 3.0-2.8 (2H, m), 2.68 (3H, s), 2.56 (3H, s), 2.5-2.2 (2H, m).

### Example 15

$(\gamma^2R)$ - $\gamma$ -[(2,5-Dichlorophenyl)thio]-2-thiazolepropanamine hydrochloride

a) [3-Oxo-3-(2-thiazolyl)propyl]carbamic acid 1,1-dimethylethyl ester

To a solution of 2-bromothiazole (5.035 g, 30.7 mmol) in dry tetrahydrofuran (125 ml) at  $-78^\circ C$  under nitrogen, was added a solution of *n*-butyllithium in hexanes (1.6 M, 17.6 ml, 28.2 mmol) over a period of 30 minutes, followed by a solution of [3-(methoxymethylamino)-3-oxopropyl]carbamic acid 1,1-dimethylethyl ester (2.976 g, 12.8 mmol) in dry tetrahydrofuran (30 ml) added over 30 minutes. The reaction mixture was allowed to warm up to  $0^\circ C$ , then quenched with saturated ammonium chloride and extracted with ethyl acetate (3 x 100 ml). The combined extracts were washed with water (3 x 50 ml) and saturated brine solution (1 x 100 ml), dried (magnesium sulphate) and concentrated *in vacuo* to leave a crude orange oil. Flash chromatography (silica, 25% ethyl acetate in isohexane) gave a pale yellow oil (2.2 g, 67%).

MS APCI +ve  $m/z$  201 ( $[M(-C_4H_9)(+H)]^+$ ).

$^1H$  NMR 300MHz ( $CDCl_3$ ) 8.01 (1H, m), 7.69 (1H, m), 5.05 (1H, br s), 3.57 (2H, q), 3.39 (2H, t), 1.46 (9H, s).

b) [(3S)-3-Hydroxy-3-(2-thiazolyl)propyl]carbamic acid 1,1-dimethylethyl ester

To a solution of (*R*)-3-methyl-CBS-oxazaborolidine (1*M* solution in toluene, 0.43 ml) in dry tetrahydrofuran (30 ml) at  $-10^{\circ}\text{C}$  under nitrogen, was added borane-tetrahydrofuran complex (1*M* in tetrahydrofuran, 2.58 ml) and the mixture was stirred at  $-10^{\circ}\text{C}$  for 15 minutes. A solution of [3-oxo-3-(2-thiazolyl)propyl]carbamic acid 1,1-dimethylethyl ester (1.1 g, 4.3 mmol) in dry tetrahydrofuran (20 ml) was added dropwise over 45 minutes and the resulting mixture was allowed to warm up to room temperature over 16 h. Methanol (10 ml) was added and the mixture was stirred at room temperature for 15 minutes before the solvent was removed at reduced pressure. Methanol (10 ml) was again added and removed at reduced pressure to leave a crude yellow oil. Flash chromatography (silica, 25 to 100% ethyl acetate in isohexane) afforded a clear gum (0.74 g, 67%).

MS APCI +ve  $m/z$  259 [(*M*+*H*)<sup>+</sup>].

c) [(3*R*)-3-[(2,5-Dichlorophenyl)thio]-3-(2-thiazolyl)propyl]carbamic acid 1,1-dimethylethyl ester.

To a solution of 2,5-dichlorothiophenol (179 mg, 1 mmol), [(3*S*)-3-hydroxy-3-(2-thiazolyl)propyl]carbamic acid 1,1-dimethylethyl ester (258 mg, 1 mmol) and triphenylphosphine (315 mg, 1.2 mmol) in dry tetrahydrofuran (30 ml) at  $0^{\circ}\text{C}$  under nitrogen, was added diisopropyl azodicarboxylate (243 mg, 0.24 ml, 1.2 mmol) dropwise over 5 minutes. The mixture was stirred at room temperature for 16 h, then concentrated *in vacuo* to leave a crude yellow gum. Flash chromatography (silica, 15% ethyl acetate in isohexane) afforded a clear oil (85 mg, 21%).

MS APCI +ve  $m/z$  419/421/423 [(*M*+*H*)<sup>+</sup>].

d) ( $\gamma^2R$ )- $\gamma$ -[(2,5-Dichlorophenyl)thio]-2-thiazolepropanamine hydrochloride

The product from Example 15(c) in dry dioxan (3 ml) was treated with 4*M* hydrochloric acid (1 ml) and the mixture stirred at room temperature for 16 h. The precipitate was collected, washed with ethyl acetate and vacuum dried to leave a white solid (39 mg, 54%).

MS APCI +ve  $m/z$  319/321 [(*M*+*H*)<sup>+</sup>].

<sup>1</sup>H NMR 300MHz (d<sub>6</sub>-DMSO) 8.06 (3H, bd s), 7.87 (1H, d), 7.80 (1H, d), 7.52 (1H, d), 7.36 (1H, d), 7.09 (1H, dd), 6.16 (1H, dd), 3.03-2.97 (2H, m), 2.45-2.33 (2H, m).

5

### Example 16

#### γ-[(2,5-Dichlorophenyl)thio]-2-oxazolepropanamine oxalate

##### a) 3-Chloro-1-(2-oxazolyl)-1-propanone

10 To a solution of oxazole (2.93 g, 42.5 mmol) in tetrahydrofuran (150 ml) at -70 °C under a nitrogen atmosphere was added n-butyllithium (2.5 M solution in hexanes, 17 ml) dropwise and the solution stirred for 20 minutes. Zinc chloride (1 M solution in diethyl ether, 84.9 ml) was added and the solution warmed to 0 °C over 45 minutes. Solid cuprous iodide (8.09 g, 42.5 mmol) was added and after 10 minutes, 3-chloropropionyl chloride  
15 (8.38 ml, 87.8 mmol) was added. After 1 h, ethyl acetate and aqueous ammonium chloride solution were added. The organic layer was separated and washed sequentially with aqueous ammonium chloride solution, water and brine. The solution was dried (sodium sulphate) and evaporated to yield the crude product as a red oil (15.5 g). This material was used without further purification.

20 <sup>1</sup>H NMR 300MHz (CDCl<sub>3</sub>) 7.86 (1H, s), 7.36 (1H, s), 3.93 (2H, t), 3.57 (2H, m).

##### b) S-α-(Azidoethyl)-2-oxazolemethanol

(R)-2-Methyl-CBS-oxazaborolidine (1M solution in toluene, 1.41 ml) was added to tetrahydrofuran (14 ml) under a nitrogen atmosphere and the solution cooled to -5 °C.  
25 Borane-tetrahydrofuran complex (1M solution in tetrahydrofuran, 14.1 ml) was added dropwise and the solution stirred for 10 minutes. A solution of the crude product from Example 16 (a) (ca. 14 mmol) in tetrahydrofuran (10 ml) was added dropwise and the reaction warmed slowly to 0 °C over 16 h. Methanol (40 ml) was cautiously added and the volatiles removed *in vacuo*. Two further methanol addition / solvent evaporation cycles  
30 were performed. The residue was purified by flash column chromatography using 5 to 30% ethyl acetate / isohexane as eluent to give a colourless oil (1.08 g). This material was taken up into dimethylsulfoxide (7 ml), solid sodium azide (604 mg) was added, and the reaction

heated at 65 °C for 16 h. After cooling to room temperature, water was added and the solution extracted three times with diethyl ether. The combined organic extracts were dried (sodium sulfate) and the solvent removed *in vacuo* to yield the sub title compound (750 mg) as an orange oil. This material was used without further purification.

5

<sup>1</sup>H NMR 300MHz (CDCl<sub>3</sub>) 7.65 (1H, d), 7.10 (1H, d), 4.96 (1H, dd), 3.53 (2H, m), 3.02 (1H, bs), 2.18 (2H, m).

c) γ-[(2,5-Dichlorophenyl)thio]-2-oxazolepropanamine oxalate

10 To a solution of triphenylphosphine (700 mg) in tetrahydrofuran (4 ml) at 0 °C was added diethyl azodicarboxylate (0.48 ml) dropwise. After 10 minutes, a solution of the product from Example 16 (b) (0.32 g) and 2,5-dichlorobenzenethiol (340 mg) in tetrahydrofuran (4 ml) was added dropwise and the solution stirred at 0 °C for 30 minutes and then at room temperature for 16 h. Further triphenylphosphine (1 g) and water (3 ml) were added and the  
15 reaction stirred for 16 h. Purification by flash chromatography on SCX resin using 0 to 7N ammonia in methanol as eluent followed by further purification by RP-HPLC gave the free base of the title product as a yellow foam (196 mg). This material was taken up in methanol and oxalic acid (1 eq.) in diethyl ether (1 ml) added. The solvent was removed *in vacuo*, and the residue washed with ethyl acetate. The resulting solid was dried *in vacuo* to  
20 yield the title product (117 mg) as a white solid.

MS APCI +ve <sup>m/z</sup> 303 [(M+H)<sup>+</sup>].

<sup>1</sup>H NMR 400MHz (d<sub>4</sub>-MeOH) 7.91 (1H, s), 7.48 (2H, m), 7.35 (1H, dd), 7.15 (1H, s), 4.75  
25 (1H, t), 3.27-3.20 (1H, m), 3.12-3.05 (1H, m), 2.55-2.39 (2H, m).

Screens

30 The pharmacological activity of compounds according to the invention was tested in the following screens.

### Screen 1

The activity of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, may be screened for nitric oxide synthase inhibiting activity by a procedure based on that of Förstermann *et al.*, Eur. J. Pharm., 1992, **225**, 161-165. Nitric  
oxide synthase converts  $^3\text{H}$ -L-arginine into  $^3\text{H}$ -L-citrulline which can be separated by cation  
exchange chromatography and quantified by liquid scintillation counting.

Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are  
cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal  
bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml  
streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm<sup>3</sup> flasks  
containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO<sub>2</sub>.

Nitric oxide synthase is produced by cells in response to interferon- $\gamma$  (IFN $\gamma$ ) and  
lipopolysaccharide (LPS). The medium from confluent culture flasks is removed and  
replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml  
IFN $\gamma$ . After a period of 17-20 hours in culture, harvesting of cells is accomplished by  
scraping the cell sheet from the flask surface into the culture medium. Cells are collected by  
centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a  
solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v)  
Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising  
leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and  
phenylmethylsulphonyl fluoride (50 mg/ml).

For the assay, 25  $\mu\text{l}$  of substrate cocktail (50 mM Tris-HCl (pH 7.5 at 20 °C), 400  $\mu\text{M}$   
NADPH, 20  $\mu\text{M}$  flavin adenine dinucleotide, 20  $\mu\text{M}$  flavin mononucleotide, 4  $\mu\text{M}$   
tetrahydrobiopterin, 12  $\mu\text{M}$  L-arginine and 0.025 mCi L-[ $^3\text{H}$ ] arginine) is added to wells of a  
96 well filter plate (0.45  $\mu\text{m}$  pore size) containing 25  $\mu\text{l}$  of a solution of test compound in 50  
mM Tris-HCl. The reaction is started by adding 50  $\mu\text{l}$  of cell lysate (prepared as above) and  
after incubation for 1 hour at room temperature is terminated by addition of 50  $\mu\text{l}$  of an  
aqueous solution of 3 mM nitroarginine and 21 mM EDTA.

Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 150 µl of a 25% aqueous slurry of Dowex 50W (Na<sup>+</sup> form) is added to the assay after which the whole is filtered into 96 well plates. 75 µl of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.

In a typical experiment basal activity is 300 dpm per 75 µl sample which is increased to 1900 dpm in the reagent controls. Compound activity is expressed as IC<sub>50</sub> (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an IC<sub>50</sub> (50% inhibitory concentration) of 10 µM, is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions obtained IC<sub>50</sub> values are calculated. Compounds that inhibit the enzyme by at least 25% at 100 µM are classed as being active and are subjected to at least one retest.

## Screen 2

Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.

Enzyme is prepared, after induction, from the cultured human colon adenocarcinoma cell line DLD1 (obtained from the European Collection of Animal Cell Culture - cell line number 90102540). DLD1 cells are cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B). Cells are routinely grown in 225 cm<sup>3</sup> flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO<sub>2</sub>.

Nitric oxide synthase is produced by cells in response to interferon-γ (IFN-γ) and interleukin-1β (IL-1β). The medium from confluent flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 250 units/ml IL-1β and 1000 units/ml IFN-γ. After a period of 17–20 hours in culture, harvesting of cells is accomplished by scraping the cell monolayer from the flask surface into the culture medium. Cells are collected by



centrifugation (1000g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20°C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors including leupeptin (2 µg/ml), soya bean trypsin inhibitor (10 µg/ml), aprotonin (5 µg/ml) and  
5 phenylmethanesulphonyl fluoride (50 µg/ml).

For the assay, 25 µl of substrate cocktail (50 mM Tris-HCl (pH 7.5), 400 µM NADPH, 20 µM flavin adenine dinucleotide, 20 µM flavin mononucleotide and 4 µM tetrahydrobiopterin) is added to the wells of a 96-well plate. Test compounds are  
10 preincubated with enzyme by adding together with 40 µl of cell lysate (prepared as above) and incubating for 1 hour at 37 °C at the end of which period 10 µl of 30 µM L-arginine and 0.025 µCi of L-[<sup>3</sup>H]-arginine in 50 mM Tris-HCl is added to start the enzymatic reaction. Incubation is continued for a further 1 hour at 37 °C. The reaction is terminated by addition of 50 µl of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.


15 Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 120 µl of a 25% aqueous slurry of Dowex 50W is added to 96 well filter plates (0.45 µm pore size). To this is added 120 µl of terminated assay mix. 75 µl of filtrate is sampled and added to the wells of 96 well plates containing solid scintillant. After allowing the samples  
20 to dry the L-citrulline is quantified by scintillation counting.

In a typical experiment basal activity is 300 dpm per 75 µl sample of reagent controls, which is increased to 3000 dpm in the presence of enzyme. Compound activity is expressed as IC<sub>50</sub> (the concentration of drug substance which gives 50% enzyme inhibition  
25 in the assay) and L-NMMA, which gives an IC<sub>50</sub> of about 0.4 µM is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions obtained IC<sub>50</sub> values are calculated.

When tested, the compounds of Examples 1 to 16 gave IC<sub>50</sub> values of less than 15 µM in at  
30 least one of the above screens, indicating that they are predicted to show useful therapeutic activity.

**CLAIMS:**

1. The use of a compound of formula (I)



wherein:

X and Y independently represent C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C≡CH, S(O)<sub>m</sub>CH<sub>3</sub>, S(O)<sub>p</sub>CF<sub>3</sub>, NO<sub>2</sub> or NHCHO;

m and p independently represent an integer 0, 1 or 2;

Z represents H or fluoro;

V represents S(O)<sub>n</sub> or NR<sup>3</sup>;

W represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO<sub>2</sub> or NR<sup>4</sup>R<sup>5</sup>; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R<sup>1</sup> and R<sup>2</sup> independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR<sup>6</sup>R<sup>7</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being

optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

or the group NR<sup>1</sup>R<sup>2</sup> together represents a 4 to 8 membered saturated azacyclic ring

5 optionally incorporating one further heteroatom selected from O, S or NR<sup>8</sup>; said ring being optionally substituted by C1 to 4 alkyl, C1 to 4 alkoxy or OH; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH or NR<sup>9</sup>R<sup>10</sup>;

R<sup>3</sup> represents H or C1 to 4 alkyl;

10

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> independently represent H or C1 to 4 alkyl;

R<sup>8</sup> represents H or C1 to 6 alkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH, NR<sup>11</sup>R<sup>12</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic  
15 ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

R<sup>11</sup> and R<sup>12</sup> independently represent H or C1 to 4 alkyl;

20

n represents an integer 0, 1 or 2;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which  
25 inhibition of nitric oxide synthase activity is beneficial.

2. The use as claimed in Claim 1 wherein it is predominantly inducible nitric oxide synthase that is inhibited.

3. The use of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.

5 4. The use as claimed in Claim 3 wherein the disease is inflammatory bowel disease.

5. The use as claimed in Claim 3 wherein the disease is rheumatoid arthritis.

6. The use as claimed in Claim 3 wherein the disease is osteoarthritis.

10

7. The use of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in the manufacture of a medicament, for the treatment or prophylaxis of pain.

15 8. The use of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in combination with a COX-2 inhibitor, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.

9. A method of treating, or reducing the risk of, human diseases or conditions in which  
20 inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, to a person suffering from, or at increased risk of, such diseases or conditions.

25 10. A method of treatment according to Claim 9 in which it is predominantly inducible nitric oxide synthase that is inhibited.

11. A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a  
30 therapeutically effective amount of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

12. The method of treatment as claimed in Claim 11 wherein the disease is inflammatory bowel disease.

13. The method of treatment as claimed in Claim 11 wherein the disease is rheumatoid arthritis.

14. The method of treatment as claimed in Claim 11 wherein the disease is osteoarthritis.

15. A method of treating, or reducing the risk of, pain in a person suffering from, or at risk of, said condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof.


16. A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a combination of a compound of formula (I), as defined in Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, with a COX-2 inhibitor.

17. A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

18. A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of diseases or conditions in which inhibition of the inducible isoform of the enzyme nitric oxide synthase activity is beneficial.

19. A pharmaceutical formulation according to Claim 17 for use in the treatment or prophylaxis of inflammatory disease.

20. A compound of formula (Ia)



wherein

X and Y independently represent C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN,

10 C≡CH, S(O)<sub>m</sub>CH<sub>3</sub>, S(O)<sub>p</sub>CF<sub>3</sub>, NO<sub>2</sub> or NHCHO;

m and p independently represent an integer 0, 1 or 2;

Z represents H or fluoro;

15

V represents S(O)<sub>n</sub> or NR<sup>3</sup>;

W represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from

20 halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO<sub>2</sub> or NR<sup>4</sup>R<sup>5</sup>; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R<sup>1</sup> and R<sup>2</sup> independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group

25 being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR<sup>6</sup>R<sup>7</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms

independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

- 5 or the group NR<sup>1</sup>R<sup>2</sup> together represents a 4 to 8 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S or NR<sup>8</sup>; said ring being optionally substituted by C1 to 4 alkyl, C1 to 4 alkoxy or OH; said alkyl group being optionally substituted by C1 to 4 alkoxy, OH or NR<sup>9</sup>R<sup>10</sup>;

- 10 R<sup>3</sup> represents H or C1 to 4 alkyl;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> independently represent H or C1 to 4 alkyl;

- R<sup>8</sup> represents H or C1 to 6 alkyl; said alkyl group being optionally substituted by C1 to 4  
15 alkoxy, OH, NR<sup>11</sup>R<sup>12</sup>, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN or NO<sub>2</sub>;

- 20 R<sup>11</sup> and R<sup>12</sup> independently represent H or C1 to 4 alkyl;

n represents an integer 0, 1 or 2;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof,

25

with the proviso that when V represents S(O)<sub>n</sub>; and R<sup>1</sup> and R<sup>2</sup> independently represent H or methyl; and W represents phenyl, optionally substituted by halogen, C1 to 4 alkyl, C1 to 3 alkoxy or CF<sub>3</sub>; or W represents thienyl, halothienyl, (C1 to 4 alkyl)-substituted-thienyl,

furanyl, pyridyl or thiazolyl; then at least one of X and Y represents OCF<sub>3</sub>, CN, C≡CH, S(O)<sub>m</sub>CH<sub>3</sub>, S(O)<sub>p</sub>CF<sub>3</sub>, NO<sub>2</sub> or NHCHO.

21. A compound of formula (1a), according to Claim 20, wherein V represents S or NH.

22. A compound of formula (1a), according to Claim 20 or Claim 21, wherein X and Y independently represent Br, Cl, CH<sub>3</sub>, CF<sub>3</sub> or CN.

23. A compound of formula (Ia), according to any one of Claims 20 to 22, wherein the substituents R<sup>1</sup> and R<sup>2</sup> are independently H or CH<sub>3</sub>.

24. A compound of formula (Ia), according to Claim 20, which is:

2-[[3-(dimethylamino)-1-phenylpropyl]amino]-4-(trifluoromethyl)-benzonitrile;

4-chloro-2-[3-(methylamino)-1-phenylpropyl]amino]-benzonitrile;

4-chloro-2-{[3-(methylamino)-1-phenylpropyl]thio}benzonitrile;

4-bromo-2-{[3-(methylamino)-1-phenylpropyl]thio}benzonitrile;

(1*R*)-N<sup>1</sup>-[2-chloro-5-(trifluoromethyl)phenyl]-N<sup>3</sup>-methyl-1-phenyl-1,3-propanediamine;

2-[[[(1*R*)-3-amino-1-phenylpropyl]amino]-4-chloro-5-fluorobenzonitrile;

4-chloro-5-fluoro-2-[[[(1*R*)-3-(methylamino)-1-phenylpropyl]amino]benzonitrile;

*N*-(5-chloro-2-nitrophenyl)-1-phenyl-3-(morpholin-1-yl)propanamine;

2-[[[(1*R*)-3-amino-1-phenylpropyl]thio]-4-chlorobenzonitrile;

2-[[[(1*R*)-3-amino-1-phenylpropyl]thio]-4-(trifluoromethyl)benzonitrile;

4-chloro-2-[methyl[3-(methylamino)-1-phenylpropyl]amino]benzonitrile;

γ-[(2,5-dichlorophenyl)thio]-2-oxazolepropanamine;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof.


25. A compound of formula (Ia), according to any one of Claims 20 to 24, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, for use as a medicament.




26. A pharmaceutical composition comprising a compound of formula (Ia) according to any one of Claims 20 to 24, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

27. A process for the preparation of a compound of formula (Ia), as defined in any one of Claims 20 to 24, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the process comprises:

(a) reaction of a compound of formula (II)




wherein X, Y, V and Z are as defined in Claim 20,  
with a compound of formula (III)




wherein W, R<sup>1</sup> and R<sup>2</sup> are as defined in Claim 20; or

(b) reaction of a compound of formula (IV)



wherein X, Y and Z are as defined in Claim 20 and L<sup>1</sup> represents a leaving group,


with a compound of formula (V)



wherein  $\text{R}^1$ ,  $\text{R}^2$ , V and W are as defined in Claim 20; or

5

(c) reaction of a compound of formula (VI)




wherein X, Y, V, W and Z are as defined in Claim 20 and  $\text{L}^2$  is a leaving group,  
with a compound of formula (VII)

10




wherein  $\text{R}^1$  and  $\text{R}^2$  are as defined in Claim 20; or

(d) reaction of a compound of formula (II)




15

wherein X, Y, V and Z are as defined in Claim 20,  
with a compound of formula (VIII)



wherein  $R^1$ ,  $R^2$  and  $W$  are as defined in Claim 20 and  $L^3$  is a leaving group; or

(e) reduction of a compound of formula (IX)



wherein  $X$ ,  $Y$ ,  $V$ ,  $W$  and  $Z$  are as defined in Claim 20 and  $G$  represents a group that upon reduction is converted into a group  $NR^1R^2$ ;

and where necessary converting the resultant compound of formula (Ia), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (Ia) into a further compound of formula (Ia); and where desired converting the resultant compound of formula (Ia) into an optical isomer thereof.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00371

## A. CLASSIFICATION OF SUBJECT MATTER

C07C 323/31, C07C 317/32, C07C 255/50, C07C 217/54, C07C 211/49,

IPC7: C07D 295/04, A61K 31/00, A61P 29/00, A61P 43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, file CAPLUS, CAPLUS accession no. 1977:189458, document no. 86:189458, Rohto Pharmaceutical Co., Ltd., Japan: "Aromatic amino ether quaternary ammonium salts"; & JP,B4,51044934,19761201 --	1-27
X	STN International, file CAPLUS, CAPLUS accession no. 1977:405817, document no. 87:5817, Rohto Pharmaceutical Co., Ltd., Japan: "Piperidinopropyl phenyl ethers"; & JP,B4,52000941,19770111 --	17-26

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

30 May 2001

Date of mailing of the international search report

31-05-2001

Name and mailing address of the ISA.

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/BS

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00371

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, file CAPLUS, CAPLUS accession no. 1978:443327, document no. 86:43327, Yan, S.J. et al, "Potential causal prophylactic antimalarial agents. Synthesis of quinoxaline, benzimidazole, and alkoxybenzene derivatives containing a novoldiamine moiety", J. Heterocycl. Chem. (1978), 15(2), 297-300 --	17-26
X	DE 2907217 A0 (ROUSSEL-UCLAF S.A.), 30 August 1979 (30.08.79), the claims --	17-26
X	EP 0273658 A1 (ELI LILLY AND COMPANY), 6 July 1988 (06.07.88), page 3, line 1 - line 55, the claims, the examples --	17-26
X	EP 0576766 A1 (NOVO NORDISK A/S), 5 January 1994 (05.01.94), page 3, the claims --	17-26
X	US 4314081 A (MOLLOY ET AL), 2 February 1982 (02.02.82), column 12, line 10 - line 67; column 14, line 50 - column 15, line 40, the claims --	17-26
X	WO 9219210 A2 (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA), 12 November 1992 (12.11.92), page 5 - page 6; page 9 - page 11, the claims --	17-26
A	US 4902710 A (FOSTER ET AL), 20 February 1990 (20.02.90), column 3, line 60 - column 5, line 65, the claims --	1-27
A	WO 9910339 A1 (PFIZER PRODUCTS INC.), 4 March 1999 (04.03.99), the claims --	1-27

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00371

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9911620 A1 (PFIZER PRODUCTS INC.), 11 March 1999 (11.03.99), the claims  -- -----	1-27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE01/00371

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9-16  
because they relate to subject matter not required to be searched by this Authority, namely:  
see next sheet
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE01/00371

Claims 9-16 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

30/04/01

International application No.

PCT/SE 01/00371

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
DE	2907217	A0	30/08/79	AT	143379 A	15/10/80
				AT	362347 B	11/05/81
				BE	874416 A	23/08/79
				CA	1116635 A	19/01/82
				CH	639637 A	30/11/83
				ES	478011 A	01/07/79
				FR	2432500 A,B	29/02/80
				GB	2017681 A,B	10/10/79
				IT	1114717 B	27/01/86
				IT	7948102 D	00/00/00
				JP	1462389 C	14/10/88
				JP	54122236 A	21/09/79
				JP	63008935 B	25/02/88
				NL	7901457 A	28/08/79
				US	4296126 A	20/10/81
-----						
EP	0273658	A1	06/07/88	SE	0273658 T3	
				AT	57924 T	15/11/90
				AU	591007 B	23/11/89
				AU	8266087 A	23/06/88
				CA	1302421 A	02/06/92
				CN	1019113 B	18/11/92
				CN	87108175 A	06/07/88
				CY	1682 A	10/10/93
				DE	3765919 D	00/00/00
				DK	664887 A	23/06/88
				EG	18230 A	30/10/92
				GR	3001207 T	30/07/92
				HK	69693 A	30/07/93
				HU	47561 A	28/03/89
				HU	206309 B	28/10/92
				IL	84863 A	29/03/92
				JP	2549681 B	30/10/96
				JP	63185946 A	01/08/88
				KR	9603808 B	22/03/96
				MX	9845 A	01/12/93
				NZ	222980 A	28/11/89
				PH	26556 A	19/08/92
				PT	86389 A,B	01/01/88
				SG	114992 G	29/01/93
				SU	1598865 A	07/10/90
				US	4956388 A	11/09/90
				US	5023269 A	11/06/91
				ZA	8709472 A	30/08/89
-----						
EP	0576766	A1	05/01/94	NONE		
-----						

## INTERNATIONAL SEARCH REPORT

Information on patent family members

30/04/01

International application No.

PCT/SE 01/00371

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	4314081	A	02/02/82	AR	205577 A	14/05/76
				AR	205578 A	14/05/76
				AR	205633 A	21/05/76
				AT	10275 A	15/08/76
				AT	237176 A	15/10/76
				AT	336000 B	12/04/77
				AT	337161 B	10/06/77
				AT	337162 B	10/06/77
				AU	7683674 A	24/06/76
				BE	824255 A	09/07/75
				BG	23212 A	12/07/77
				BG	26192 A	15/02/79
				BG	60761 B	29/02/96
				CA	1051034 A	20/03/79
				CH	609331 A	28/02/79
				CH	609332 A	28/02/79
				CH	609675 A	15/03/79
				CS	189680 B	30/04/79
				CS	189698 B	30/04/79
				CS	196397 B	31/03/80
				DD	118613 A	12/03/76
				DE	2500110 A,C	17/07/75
				DK	140430 B,C	27/08/79
				DK	688974 A	01/09/75
				ES	433720 A	01/12/76
				FR	2257288 A,B	08/08/75
				GB	1493961 A	07/12/77
				IE	40346 B	09/05/79
				JP	1264510 C	16/05/85
				JP	50101333 A	11/08/75
				JP	59039418 B	22/09/84
				KR	8001009 A	22/09/80
				NL	181654 B,C	04/05/87
				NL	7500186 A	14/07/75
				PH	11652 A	08/05/78
				RO	69763 A	26/02/82
				RO	70660 A	26/09/83
				SE	412906 B,C	24/03/80
				SE	7500215 A	11/07/75
				SU	1005655 A	15/03/83
				US	4018895 A	19/04/77
				US	4194009 A	18/03/80
				US	4313896 A	02/02/82
				US	4584404 A	22/04/86
				US	4626549 A	02/12/86
				YU	3275 A	18/06/82
				YU	36915 B	31/08/84
				YU	37307 B	31/08/84
				YU	37308 B	31/08/84
				YU	121481 A	27/04/83
				YU	121581 A	27/04/83
				ZA	7500032 A	25/08/76
				AT	237076 A	15/10/76
				HU	173723 B	28/07/79
				IL	46387 A	31/08/77

# INTERNATIONAL SEARCH REPORT

Information on patent family members

30/04/01

International application No.

PCT/SE 01/00371

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	4314081	A	02/02/82	MX	4949 E	12/01/83
				MX	4983 E	31/01/83
				SU	583743 A	05/12/77
				SU	613716 A	30/06/78
-----						
WO	9219210	A2	12/11/92	US	5320825 A	14/06/94
-----						
US	4902710	A	20/02/90	AT	102920 T	15/04/94
				CA	2005173 A	14/06/90
				DE	68913930 D,T	14/07/94
				EP	0373836 A,B	20/06/90
				SE	0373836 T3	
				JP	2218661 A	31/08/90
-----						
WO	9910339	A1	04/03/99	AP	9801330 D	00/00/00
				AU	8458898 A	16/03/99
				BG	104138 A	30/11/00
				BR	9811555 A	12/09/00
				CN	1268133 T	27/09/00
				EP	1007520 A	14/06/00
				HR	980470 A	30/06/99
				NO	20000958 A	14/04/00
				PL	338987 A	04/12/00
				SK	1402000 A	11/07/00
-----						
WO	9911620	A1	11/03/99	AP	9801331 D	00/00/00
				AU	8458698 A	22/03/99
				BR	9811921 A	15/08/00
				CN	1268122 T	27/09/00
				EP	1007512 A	14/06/00
				HR	980476 A	30/06/99
				NO	20000957 A	25/02/00
				PL	339008 A	04/12/00
-----						